Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + cyclophosphamide + vinorelbine
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Anlotinib + cyclophosphamide + vinorelbine is a combination chemotherapy and targeted therapy regimen being investigated by Sun Yat-sen University for the maintenance treatment of children with intermediate-high risk rhabdomyosarcoma. Anlotinib is a multi-targeted tyrosine kinase inhibitor that suppresses tumor angiogenesis and growth by inhibiting VEGFR1/2/3, FGFR1-4, PDGFRα/β, and c-Kit. Cyclophosphamide is an alkylating agent that cross-links DNA, preventing cell replication. Vinorelbine is a semi-synthetic vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and inducing mitotic arrest. This oral regimen is evaluated in Phase II trials to improve long-term survival and response duration in pediatric patients following standard therapy.
- Other names
- Anlotinib+Cyclophosphamide+Vinorelbine
02
Targets
TUBB (Tubulin (alpha and beta subunits))KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on anlotinib + cyclophosphamide + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + cyclophosphamide + vinorelbine.